Natural Investments LLC Invests $392,000 in Edwards Lifesciences Co. (NYSE:EW)

Natural Investments LLC acquired a new position in Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,303 shares of the medical research company’s stock, valued at approximately $392,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Abacus Planning Group Inc. grew its position in shares of Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after buying an additional 140 shares during the period. Bowman & Co S.C. increased its holdings in Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after acquiring an additional 148 shares in the last quarter. Pegasus Asset Management Inc. grew its holdings in Edwards Lifesciences by 0.4% during the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after buying an additional 159 shares in the last quarter. Mount Yale Investment Advisors LLC grew its holdings in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after purchasing an additional 162 shares in the last quarter. Finally, Cooper Financial Group grew its holdings in shares of Edwards Lifesciences by 2.8% in the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after purchasing an additional 175 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $68.49 on Wednesday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock has a fifty day moving average of $72.03 and a 200-day moving average of $70.35. The company has a market capitalization of $40.26 billion, a PE ratio of 9.83, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares of the company’s stock, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 44,303 shares of company stock valued at $3,255,356. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Evercore ISI decreased their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Barclays lifted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. The Goldman Sachs Group boosted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. Finally, Truist Financial restated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.